Trinity Biotech plc (TRIB)
NASDAQ: TRIB · Real-Time Price · USD
0.7651
+0.0731 (10.56%)
At close: Mar 13, 2026, 4:00 PM EDT
0.7503
-0.0148 (-1.93%)
After-hours: Mar 13, 2026, 4:55 PM EDT
Trinity Biotech Revenue
Trinity Biotech had revenue of $9.20M in the quarter ending June 30, 2025, a decrease of -41.93%. This brings the company's revenue in the last twelve months to $49.41M, down -15.76% year-over-year. In the year 2024, Trinity Biotech had annual revenue of $61.56M with 8.31% growth.
Revenue (ttm)
$49.41M
Revenue Growth
-15.76%
P/S Ratio
0.26
Revenue / Employee
$121,122
Employees
401
Market Cap
14.32M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 61.56M | 4.72M | 8.31% |
| Dec 31, 2023 | 56.83M | -5.69M | -9.10% |
| Dec 31, 2022 | 62.52M | -18.63M | -22.96% |
| Dec 31, 2021 | 81.15M | -20.83M | -20.43% |
| Dec 31, 2020 | 101.98M | 11.55M | 12.77% |
| Dec 31, 2019 | 90.44M | -6.60M | -6.80% |
| Dec 31, 2018 | 97.04M | -2.11M | -2.12% |
| Dec 31, 2017 | 99.14M | -471.00K | -0.47% |
| Dec 31, 2016 | 99.61M | -584.00K | -0.58% |
| Dec 31, 2015 | 100.20M | -4.68M | -4.46% |
| Dec 31, 2014 | 104.87M | 13.66M | 14.97% |
| Dec 31, 2013 | 91.22M | 8.71M | 10.55% |
| Dec 31, 2012 | 82.51M | 4.56M | 5.85% |
| Dec 31, 2011 | 77.95M | -11.69M | -13.04% |
| Dec 31, 2010 | 89.64M | -36.27M | -28.81% |
| Dec 31, 2009 | 125.91M | -14.23M | -10.16% |
| Dec 31, 2008 | 140.14M | -3.48M | -2.42% |
| Dec 31, 2007 | 143.62M | 24.94M | 21.02% |
| Dec 31, 2006 | 118.67M | 20.11M | 20.41% |
| Dec 31, 2005 | 98.56M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IRIDEX | 50.65M |
| Lifeward | 24.50M |
| Vivos Therapeutics | 17.32M |
| Beyond Air | 6.92M |
| Tenon Medical | 3.23M |
| Sintx Technologies | 1.27M |
| Nexalin Technology | 156.93K |
| Adagio Medical Holdings | 137.00K |
TRIB News
- 1 day ago - Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System - GlobeNewsWire
- 2 days ago - Trinity Biotech Senior Executives to Attend ATTD 2026 to Advance Collaborations Following Strong Progress in CGM Program - GlobeNewsWire
- 3 days ago - Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform - GlobeNewsWire
- 3 days ago - Trinity Biotech Provides Business and Trading Update - GlobeNewsWire
- 16 days ago - Trinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives - GlobeNewsWire
- 21 days ago - Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares - GlobeNewsWire
- 4 weeks ago - Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 4 weeks ago - Trinity Biotech Secures Regulatory Approval for Commencement of Upstream Manufacturing Activities of Uni-Gold™ HIV Rapid Test Under Its Offshored and Outsourced Model, Supporting Financial Performance Transformation - GlobeNewsWire